Compares how the body absorbs different injected forms of AZD9550 and AZD6234
Compares blood levels of injected AZD9550 and AZD6234 formulations in healthy adults.
Plain-language title generated from the registry record
Registry title: A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234
Key facts
- Where
- Ruddington, United KingdomSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT07911514, who can take part
Where in United Kingdom
- RuddingtonRuddington, United KingdomNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07911514
- Record updated
- 2 November 2026
- Original description
This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of two test medicines, AZD9550 and AZD6234.Read full original descriptionShow less
A Phase I, Single-Dose, Randomised, Parallel-Group, Open-Label Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234 in Participants Living With Overweight or Obesity
This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of two test medicines, AZD9550 and AZD6234.
This study will take place at one site in Nottingham, United Kingdom, and will randomize 60 healthy men and women aged 18-55 years living with overweight/obesity.
Inclusion: Healthy males or non-pregnant, non-lactating females aged 18 to 55 years inclusive; BMI of 25.0 to 35.0 kg/m2 inclusive and weight ≥50 kg.
Exclusion: Prior or planned bariatric surgery or placement of a weight loss device; Participants who have received any IMP in the last 90 days prior to dosing; Participants who have previously received AZD9550 and/or AZD6234; Treatment with prescription or non-prescription medication intended for weight loss within 3 months before screening; Treatment with a GLP-1-containing preparation within 3 months before screening; Treatment with an amylin analogue containing preparation within 30 days before screening; Treatment with medication for diabetes within 3 months before screening; Treatment with medication associated with significant weight gain in the 3 months before screening; Plasma donation within 3 months of screening or any blood donation/loss more than 500 mL within 3 months before screening; Use of any prescribed or non-prescribed medication including antacids, gastric pH modifying agents, analgesics, herbal remedies, vitamins and minerals within 2 weeks of dosing; Use of drugs or herbal medications with CYP3A4 enzyme-inducing properties within 3 weeks of dosing; History of any clinically important disease or disorder; History or presence of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory, neurological, psychiatric or GI disorder including a history of pancreatitis or gall stones; History of suicidal ideation or behaviour; Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of dosing; History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, or history of hypersensitivity to any component of the AZD6234 or AZD9550 drug products; Skin disorder/condition or tattoos in the abdominal area of the proposed injection site which can interfere with study assessments; Evidence of renal impairment; Current smokers or known or suspected history of alcohol or drug abuse; HbA1c ≥6.5% (≥48 mmol/mol); Participants who do not have suitable veins for multiple venepunctures/cannulation; Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis; Basal calcitonin level > 50 ng/L; Any clinically significant abnormal findings in vital signs; Any clinically significant abnormalities on 12-lead ECG; Females who are pregnant or lactating; Excessive intake of caffeine-containing drinks or food.